Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presentation AHA 2022

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presenter: Gregg W. Stone

November 07, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Conference News AHA 2014

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Yael L. Maxwell

November 17, 2014

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.